Corporate InformationCorporate Profile
- Name
- Human Life CORD Japan Inc.
- Incorporation
- April 5, 2017
- Address
- [Headquarters]
1-9-10, Nihonbashi-horidomecho, Chuo-ku, Tokyo, Japan
Nihonbashi Life Science Building 7, 5F
[TIP lab]
Institute of Science Tokyo
1-5-45 Yushima, Bunkyo-ku, Tokyo, JAPAN - Executives
-
President and Representative Director (CEO) Masamitsu Harata
Director Nobutoshi Matsushita
Outside Director Tetsuo Yamanaka
Outside Director Misao Konishi
Outside Director Takaaki Nakajima
Outside Director Shintaro Sengoku
Outside Auditor (Full time) Hiroshi Nakamura
Outside Auditor (Part-time) Daisuke Fujioka
Outside Auditor (Part-time) Maya Ito - Senior Advisor
-
Kazuo Asakawa (Corporate Strategy)
Hirotaka Yabuki (Corporate Strategy)
Andy C. Ye (Global Strategy)
Keiya Ozawa (Medical)
Tokiko Nagamura (Medical)
Satoshi Teramukai (Biostatistics) - Number of employees (including temporary staff)
- 28 (as of January 2025)
- Business Activities
- R&D, manufacturing, and sales of regenerative medicine products
- Capital
- 3,645 million yen
- Cooperative organizations
-
◆Academia
The Institute of Medical Science, the University of Tokyo
Institute of Science Tokyo
Jichi Medical University
◆Business Affiliates
Inabata & Co., Ltd.
Rohto Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd.
Alfresa Corporation
Alfresa Holdings Corporation
AutoPhagyGO
◆Independent Auditors
EY Ernst & Young ShinNihon LLC - Member organizations
-
LINK-J https://www.link-j.org/
ME-BYO http://www.pref.kanagawa.jp/docs/cz6/me-byokaizen/
JSRM https://www.jsrm.jp/
FIRM https://firm.or.jp/
JPA https://nanbyo.jp/ - Banks
-
Mizuho Bank, Marunouchi Chuo Branch
Sumitomo Mitsui Banking Corporation, Nihonbashi Branch
Kiraboshi Bank, Shinbashi Branch
Corporate InformationHistory
- 2017
-
Human Life CORD Japan Inc. established in Chiyoda-ku, Tokyo
Entered into a business alliance with Tissue Genesis
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo
Concluded a joint research agreement with Kansai Medical University
Began sales of Tissue Genesis products - 2018
-
Transfer offices to Chuo-ku, Tokyo. (LINK-J member)
First employee joined the company
Concluded an exclusive sales agent agreement with Inabata & Co., Ltd.
- 2019
-
Concluded a license agreement with the University of Tokyo
First-class medical device manufacturing and sales business license obtained
Concluded a joint R&D contract with StemMed
Entered into a capital and business alliance with Alfresa Holdings Corporation
Entered into a capital alliance with Rohto Pharmaceutical Co., Ltd.
Received Tokyo Metropolitan Governor's Award for Excellence at the Tokyo Venture Company Championship - 2020
-
Procured a total of ¥1.1 billion through a capital increase through a third-party allocation of shares
Transitioned to a company with statutory auditors
Study initiation for acute respiratory distress syndrome (ARDS) associated with COVID-19
Selected for AMED "Therapeutic Drug Development for COVID-19"
Established "Human Life CORD Applied Cellular Medicine Laboratory" at Nagoya University
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo regarding the establishment of a stable supply system - 2021
-
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo for the treatment of progeria (Werner's Syndrome)
Launch of IMSUT-HLC Cell Processing Facility, a cell processing manufacturing facility - 2022
-
Procured a total of 854 million yen through a third-party allocation of shares
Concluded a manufacturing outsourcing agreement with Rohto Pharmaceutical Co., Ltd.
End of "Human Life CORD Applied Cellular Medicine Laboratory" at Nagoya University
Initiation of clinical trials for non-infectious pulmonary complications after hematopoietic stem cell transplantation - 2023
-
Japan Open Innovation Prize for Minister of Health, Labor and Welfare Award
IMSUT-HLC Cell Processing Facility obtained permission to manufacturing for regenerative medicine products
Joint business agreement with Mochida Pharmaceutical Ltd. on “HLC-001”
Selected for the startup support program "J-Startup" by the Ministry of Economy, Trade and Industry
Joint research agreement with Institute of Science Tokyo on recalcitrant autoimmune diseases
Human Life CORD Obtained permission to manufacturing and sales for regenerative medicine products - 2024
- Kagoshima University, our joint research partner, selected for AMED ‘SmartBio for Drug Discovery’ Program
- 2025
-
Kagoshima University, our joint research partner, selected for AMED ‘SmartBio for Drug Discovery’ Program
Collaborated with New York Blood Center as U.S. manufacturing base
Sarcopenia biomarker study launched in Brazil
Designated by MHLW as an Orphan Regenerative Medical Product
Selected for the METI 2025 Healthcare Industry Global Expansion Promotion Project
Signed Binding MOU with a local conglomerate for business expansion in MENA (Middle East & North Africa)
Corporate Information
Back to Top Page